U.S. Markets closed

Taking Stock of Gilead Sciences’ Key Developments

Kenneth Smith
Taking Stock of Gilead Sciences’ Key Developments

During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.